Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with very poor prognosis and few advances in its treatment. Recently, fast-growing cancer immunotherapy provides a glimmer of hope for GBM treatment. Adoptive cell therapy (ACT) aims at infusing immune cells with direct a...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00059/full |
id |
doaj-7bb57ef2b887421bbc1b2e709c0fadf8 |
---|---|
record_format |
Article |
spelling |
doaj-7bb57ef2b887421bbc1b2e709c0fadf82020-11-25T02:36:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-01-011010.3389/fonc.2020.00059501154Adoptive Cell Therapy: A Novel and Potential Immunotherapy for GlioblastomaJingyu Wang0Fang Shen1Ying Yao2Lin-lin Wang3Yongjian Zhu4Jue Hu5Department of Neurosurgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Orthopaedic Surgery's Spine Division, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, ChinaDepartment of Neurosurgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Basic Medicine Sciences, School of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of Neurosurgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, ChinaGlioblastoma multiforme (GBM) is the most common primary brain tumor in adults with very poor prognosis and few advances in its treatment. Recently, fast-growing cancer immunotherapy provides a glimmer of hope for GBM treatment. Adoptive cell therapy (ACT) aims at infusing immune cells with direct anti-tumor activity, including tumor-infiltrating lymphocyte (TIL) transfer and genetically engineered T cells transfer. For example, complete regressions in patients with melanoma and refractory lymphoma have been shown by using naturally tumor-reactive T cells and genetically engineered T cells expressing the chimeric anti-CD19 receptor, respectively. Recently, the administration of ACT showed therapeutic potentials for GBM treatment as well. In this review, we summarize the success of ACT in the treatment of cancer and provide approaches to overcome some challenges of ACT to allow its adoption for GBM treatment.https://www.frontiersin.org/article/10.3389/fonc.2020.00059/fulladoptive cell therapyGlioblastoma multiformechimeric antigen receptorT cell receptortumor-infiltrating lymphocyte |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jingyu Wang Fang Shen Ying Yao Lin-lin Wang Yongjian Zhu Jue Hu |
spellingShingle |
Jingyu Wang Fang Shen Ying Yao Lin-lin Wang Yongjian Zhu Jue Hu Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma Frontiers in Oncology adoptive cell therapy Glioblastoma multiforme chimeric antigen receptor T cell receptor tumor-infiltrating lymphocyte |
author_facet |
Jingyu Wang Fang Shen Ying Yao Lin-lin Wang Yongjian Zhu Jue Hu |
author_sort |
Jingyu Wang |
title |
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
title_short |
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
title_full |
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
title_fullStr |
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
title_full_unstemmed |
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
title_sort |
adoptive cell therapy: a novel and potential immunotherapy for glioblastoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-01-01 |
description |
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with very poor prognosis and few advances in its treatment. Recently, fast-growing cancer immunotherapy provides a glimmer of hope for GBM treatment. Adoptive cell therapy (ACT) aims at infusing immune cells with direct anti-tumor activity, including tumor-infiltrating lymphocyte (TIL) transfer and genetically engineered T cells transfer. For example, complete regressions in patients with melanoma and refractory lymphoma have been shown by using naturally tumor-reactive T cells and genetically engineered T cells expressing the chimeric anti-CD19 receptor, respectively. Recently, the administration of ACT showed therapeutic potentials for GBM treatment as well. In this review, we summarize the success of ACT in the treatment of cancer and provide approaches to overcome some challenges of ACT to allow its adoption for GBM treatment. |
topic |
adoptive cell therapy Glioblastoma multiforme chimeric antigen receptor T cell receptor tumor-infiltrating lymphocyte |
url |
https://www.frontiersin.org/article/10.3389/fonc.2020.00059/full |
work_keys_str_mv |
AT jingyuwang adoptivecelltherapyanovelandpotentialimmunotherapyforglioblastoma AT fangshen adoptivecelltherapyanovelandpotentialimmunotherapyforglioblastoma AT yingyao adoptivecelltherapyanovelandpotentialimmunotherapyforglioblastoma AT linlinwang adoptivecelltherapyanovelandpotentialimmunotherapyforglioblastoma AT yongjianzhu adoptivecelltherapyanovelandpotentialimmunotherapyforglioblastoma AT juehu adoptivecelltherapyanovelandpotentialimmunotherapyforglioblastoma |
_version_ |
1724800332726272000 |